title: The effect of low-dose marine n-3 fatty acids on the biosynthesis of pro-inflammatory 5-lipoxygenase pathway metabolites in overweight subjects: a randomized controlled trial.
abstract: BACKGROUND
  Marine n-3 polyunsaturated fatty acids (PUFA) have a variety of anti-inflammatory properties. This study evaluated the effect of n-3 PUFA in a low, but recommended cardioprotective dosage on the formation of 5-lipoxygenase pathway metabolites in overweight subjects.
  
  
  METHODS
  Fifty subjects were randomized to 1.1g of n-3 PUFA or olive oil for 6 weeks.
  
  
  RESULTS
  Leukotriene B(4) formation decreased by 14% in the n-3 PUFA group which proved to be significant within the group (p=0.005) but not between groups (p=0.25). The formation of 5-hydroxyeicosatetraenoic acid (5-HETE) did not differ significantly between the groups. In the n-3 PUFA group, both 5-hydroxyeicosapentaenoic (5-HEPE) acid and leukotriene B(5) increased significantly compared to the control group (p<0.001).
  
  
  CONCLUSIONS
  In conclusion, we did not observe any significant net anti-inflammatory effect on the 5-lipoxygenase pathway from a daily supplement of 1.1g marine n-3 PUFA for 6 weeks.
authors: Department of Cardiology, Center for Cardiovascular Research, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark. mrsn@rn.dk
authors: M S
authors: MS
authors: Nielsen
authors: A
authors: A
authors: Gammelmark
authors: T
authors: T
authors: Madsen
authors: T
authors: T
authors: Obel
authors: I
authors: I
authors: Aardestrup
authors: E B
authors: EB
authors: Schmidt
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism*; D002316:Cardiotonic Agents / Q000008:administration & dosage; D002462:Cell Membrane / Q000378:metabolism; D004311:Double-Blind Method; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives / Q000096:biosynthesis; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000096:biosynthesis; D007975:Leukotriene B4 / Q000031:analogs & derivatives / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009504:Neutrophils / Q000378:metabolism; D056128:Obesity, Abdominal / Q000188:drug therapy* / Q000473:pathology; D050177:Overweight / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D002316:Cardiotonic Agents; D015525:Fatty Acids, Omega-3; D006893:Hydroxyeicosatetraenoic Acids; D007975:Leukotriene B4; C022022:5-hydroxy-6,8,11,14-eicosatetraenoic acid; C040212:leukotriene B5; C058722:5-hydroxy-6,8,11,14,17-eicosapentaenoic acid; D015118:Eicosapentaenoic Acid; D001094:Arachidonate 5-Lipoxygenase